• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

寰椎药物洗脱冠状动脉支架抑制绵羊模型中的内膜增生。

Atlas Drug-Eluting Coronary Stents Inhibit Neointimal Hyperplasia in Sheep Modeling.

作者信息

Dinc Rasit, Yerebakan Halit

机构信息

INVAMED Medical Innovation Institute, Ankara, Turkey.

Department of Cardiovascular Surgery, Yeditepe University, Istanbul, Turkey.

出版信息

Acta Cardiol Sin. 2024 Sep;40(5):585-594. doi: 10.6515/ACS.202409_40(5).20240618A.

DOI:10.6515/ACS.202409_40(5).20240618A
PMID:39308654
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11413949/
Abstract

BACKGROUND

Coronary artery disease (CAD) is one of the leading causes of mortality and morbidity worldwide. Many patients with CAD require mechanical revascularization. However, restenosis after minimally invasive interventions is a major problem for these patients. Fortunately, the controlled drug delivery properties of drug-eluting stents seem to be able to overcome this problem. In this study, the pharmacodynamic and pharmacokinetic properties of Atlas Drug-eluting Coronary Stents coated with poly (lactic acid-coglycolic acid) (PLGA) were evaluated.

MATERIALS AND METHODS

This study included 20 non-atherosclerotic female sheep divided into 4 groups that included 4 study and 1 control animal randomly assigned to each group. Animals in the study groups were stented with Atlas Drug-eluting Coronary Stents, and the pharmacodynamic and pharmacokinetic properties were evaluated.

RESULTS

Sirolimus was shown to have a statistically important effect on the vascular endothelium. With time, the decrease in sirolimus in blood samples was statistically significant. Two animals died after implantation; however no clinically significant side effects were observed in the others.

CONCLUSIONS

The results in this study showed a significant reduction in neointimal hyperplasia after experimental implantation of Atlas Drug-eluting Coronary Stents coated with PLGA polymer. Pharmacokinetic studies also showed that the stent did not release a significant amount of sirolimus after 28 days.

摘要

背景

冠状动脉疾病(CAD)是全球范围内导致死亡和发病的主要原因之一。许多CAD患者需要进行机械血运重建。然而,微创干预后的再狭窄是这些患者面临的一个主要问题。幸运的是,药物洗脱支架的可控药物递送特性似乎能够克服这一问题。在本研究中,评估了涂覆聚乳酸-乙醇酸共聚物(PLGA)的阿特拉斯药物洗脱冠状动脉支架的药效学和药代动力学特性。

材料与方法

本研究纳入20只非动脉粥样硬化的雌性绵羊,随机分为4组,每组包括4只研究动物和1只对照动物。研究组的动物植入阿特拉斯药物洗脱冠状动脉支架,并评估其药效学和药代动力学特性。

结果

西罗莫司对血管内皮显示出具有统计学意义的重要作用。随着时间的推移,血样中西罗莫司的减少具有统计学意义。植入后有2只动物死亡;然而,其他动物未观察到具有临床意义的副作用。

结论

本研究结果表明,植入涂覆PLGA聚合物的阿特拉斯药物洗脱冠状动脉支架后,内膜增生显著减少。药代动力学研究还表明,28天后该支架未释放大量西罗莫司。

相似文献

1
Atlas Drug-Eluting Coronary Stents Inhibit Neointimal Hyperplasia in Sheep Modeling.寰椎药物洗脱冠状动脉支架抑制绵羊模型中的内膜增生。
Acta Cardiol Sin. 2024 Sep;40(5):585-594. doi: 10.6515/ACS.202409_40(5).20240618A.
2
Perspectives of drug-eluting stents: the next revolution.药物洗脱支架的前景:下一场革命。
Am J Cardiovasc Drugs. 2002;2(3):163-72. doi: 10.2165/00129784-200202030-00004.
3
Intracoronary Stents冠状动脉内支架
4
Vascular response and mechanical integrity of the new biodegradable polymer coated sirolimus-eluting PROLIM stent implanted in porcine coronary arteries.新型可生物降解聚合物涂层西罗莫司洗脱 PROLIM 支架在猪冠状动脉中的血管反应和机械完整性。
Kardiol Pol. 2012;70(7):703-11.
5
[Experimental study of Mytrolimus-eluting stents on preventing restenosis in porcine coronary model].[霉酚酸酯洗脱支架预防猪冠状动脉模型再狭窄的实验研究]
Zhonghua Xin Xue Guan Bing Za Zhi. 2005 Jun;33(6):561-4.
6
INtimal hyPerplasia evAluated by oCT in de novo COROnary lesions treated by drug-eluting balloon and bare-metal stent (IN-PACT CORO): study protocol for a randomized controlled trial.OCT 评价药物涂层球囊与金属裸支架治疗初发冠状动脉病变的内膜增生(IN-PACT CORO):一项随机对照试验的研究方案。
Trials. 2012 May 6;13:55. doi: 10.1186/1745-6215-13-55.
7
Drug-eluting stents.药物洗脱支架
Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319.
8
9
Sirolimus eluting stent in the treatment of atherosclerosis coronary artery disease.西罗莫司洗脱支架治疗动脉粥样硬化性冠状动脉疾病。
Minerva Cardioangiol. 2002 Oct;50(5):405-18.
10
Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent.西罗莫司洗脱支架的28天疗效及药代动力学
Coron Artery Dis. 2002 May;13(3):183-8. doi: 10.1097/00019501-200205000-00008.

引用本文的文献

1
A review of the current state in neointimal hyperplasia development following endovascular intervention and minor emphasis on new horizons in immunotherapy.血管内介入术后新生内膜增生发展现状的综述以及对免疫治疗新前景的简要阐述。
Transl Clin Pharmacol. 2023 Dec;31(4):191-201. doi: 10.12793/tcp.2023.31.e18. Epub 2023 Nov 22.

本文引用的文献

1
Five-Year Clinical Outcome of the Biodegradable Polymer Ultrathin Strut Sirolimus-Eluting Stent Compared to the Biodegradable Polymer Biolimus-Eluting Stent in Patients Treated With Percutaneous Coronary Intervention: From the SORT OUT VII Trial.经皮冠状动脉介入治疗患者中,生物可降解聚合物超薄支柱西罗莫司洗脱支架与生物可降解聚合物比伐卢定洗脱支架的五年临床结局:来自SORT OUT VII试验
Circ Cardiovasc Interv. 2023 Jan;16(1):e012332. doi: 10.1161/CIRCINTERVENTIONS.122.012332. Epub 2023 Jan 17.
2
Ten-year clinical outcomes of drug-eluting stents with different polymer coating strategies by degree of coronary calcification: a pooled analysis of the ISAR-TEST 4 and 5 randomised trials.不同聚合物涂层策略药物洗脱支架治疗冠状动脉钙化程度的 10 年临床结果:ISAR-TEST 4 和 5 随机试验的汇总分析。
EuroIntervention. 2023 Feb 20;18(14):1188-1196. doi: 10.4244/EIJ-D-22-00781.
3
Revascularization strategies for patients with established chronic coronary syndrome.已确诊慢性冠状动脉综合征患者的血运重建策略。
Eur J Clin Invest. 2022 Aug;52(8):e13787. doi: 10.1111/eci.13787. Epub 2022 Apr 29.
4
In Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches.支架内新生动脉粥样硬化:病理生理学、临床意义、预防及治疗方法
Life (Basel). 2022 Mar 8;12(3):393. doi: 10.3390/life12030393.
5
Late neointimal volume reduction is observed following biodegradable polymer-based drug eluting stent in porcine model.在猪模型中,观察到使用基于可生物降解聚合物的药物洗脱支架后晚期新生内膜体积减小。
Int J Cardiol Heart Vasc. 2021 May 11;34:100792. doi: 10.1016/j.ijcha.2021.100792. eCollection 2021 Jun.
6
Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study.全球心血管疾病负担及危险因素, 1990-2019:来自 GBD 2019 研究的更新。
J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. doi: 10.1016/j.jacc.2020.11.010.
7
Thin, very thin, or ultrathin-strut biodegradable or durable polymer-coated drug-eluting stents.薄型、极薄型或超薄型药物洗脱支架,采用生物可降解或耐用聚合物涂层。
Curr Opin Cardiol. 2020 Nov;35(6):705-711. doi: 10.1097/HCO.0000000000000786.
8
The 2010s in clinical drug-eluting stent and bioresorbable scaffold research: a Dutch perspective.2010年代临床药物洗脱支架和生物可吸收支架研究:荷兰视角
Neth Heart J. 2020 Aug;28(Suppl 1):78-87. doi: 10.1007/s12471-020-01442-w.
9
The impact of ureteral stent type on patient symptoms as determined by the ureteral stent symptom questionnaire: a prospective, randomized, controlled study.输尿管支架症状问卷确定的输尿管支架类型对患者症状的影响:一项前瞻性、随机、对照研究。
J Endourol. 2015 Mar;29(3):367-71. doi: 10.1089/end.2014.0294. Epub 2014 Oct 9.
10
Stent selection to minimize the risk of stent thrombosis.选择支架以将支架内血栓形成的风险降至最低。
Curr Opin Cardiol. 2014 Nov;29(6):578-85. doi: 10.1097/HCO.0000000000000102.